Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia

Acta Pharmacologica Sinica

Volumn 27, Issue 3, 2006, Pages 381-386

  Zhou, Zhi Ling ^b   Li, Xin ^a   Peng, Huai Yan ^c   Yu, Xi Yong ^b   Yang, Ming ^b   Su, Feng Li ^a   Wang, Feng ^a   Zhu, Rong Hua ^a   Deng, Chun Yu ^b   Lin, Qiu Xiong ^b   Wang, Chuan Yue ^d   Li, Wen Biao ^d   Lin, Shu Guang ^b   Li, Huan De ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

9 hydroxyrisperidone; Pharmacokinetics; Risperidone; Schizophrenia

Indexed keywords

9 HYDROXYRISPERIDONE; PROLACTIN; RISPERIDONE;

ABNORMAL DREAMING; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CAUCASIAN; CHINESE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CORRELATION ANALYSIS; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DYSPEPSIA; EXTRAPYRAMIDAL SYNDROME; FEMALE; GALACTORRHEA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INSOMNIA; MASS SPECTROMETRY; MENTAL PATIENT; MULTIPLE DRUG DOSE; MYALGIA; NAUSEA; PAIN; PARAMETER; PROLACTIN BLOOD LEVEL; SCHIZOPHRENIA; SOMNOLENCE; TACHYCARDIA; VALIDATION PROCESS; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; FEMALE; HUMANS; ISOXAZOLES; MIDDLE AGED; PYRIMIDINES; RISPERIDONE; SCHIZOPHRENIA;

EID: 33644823443     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2006.00256.x     Document Type: Article

References (45)

1. Janssen PA Niemegeers CJ Awouters F Schellekens KH Megens AA Meert TF. Pharmacology of risperidone (R64766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties J Pharmacol Exp Ther 1988 244 685 93
2. Marder SR Davis DM Chouinard D. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials J Clin Psychiatry 1997 58 538 46
3. Mesotten F Suy E Pietquin M Burton P Heylen S Gelders Y. Therapeutic effect and safety of increasing doses of risperidone (R64766) in psychotic patients Psychopharmacology 1989 99 445 9
4. Huang F Lasseter KC Janssens L. Pharmacokinetics and safety assessments of Galantamine and Risperidone after the two drugs are administered alone and together J Clin Pharmacol 2002 42 1341 51
5. He H Richardson JS. A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors Int Clin Psycho-pharmacol 1995 10 19 30
6. Mannens G Huang ML Meuldermans W. Absorption, metabolism, and excretion of risperidone in humans Drug Metab Dispos 1993 21 1134 41
7. Koymans L Vermeulen NP van Acker SA. A predictive model for substrates of cytochrome P450-debrisoquine (2D6) Chem Res Toxicol 1992 5 211 9
8. Beijsterveldt V Geerts JFR Lseysen JE. The regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat Psychopharmacol 1993 15 371 9
9. Fang J Bourin M Baker GB. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4 Naunyn Schmiedebergs Arch Pharmacol 1999 359 147 51
10. Yasui-Furukori N Hidestrand M Spina E. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes Drug Metab Dispos 2001 29 1263 8
11. Nyberg S Dahl ML Halldin C. A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone Psychopharmacology (Berl) 1995 119 345 8
12. Huang ML van Peer A Woestenborghs R De Coster R Heykants J Jansen AA et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects Clin Pharmacol Ther 1993 54 257 68
13. Heykants J Huang ML Mannens G Meuldermans W Snoeck E Van Beijsterveldt L et al. The pharmacokinetics of risperidone in humans: a summary J Clin Psychiatry 1994 55 Suppl 13 7
14. Ereshefsky L Lacombe S. Pharmacological profile of risperidone Can J Psychiatry 1993 38 Suppl 3 S80 8
15. Wei X. To review the data of epidemiological survey of schizophrenia Chin Gen Practice 2003 8 669 70
16. Shen YC. Discussion of the data of prevalence survey of all kinds of mental diseases Chin J Neurol Psychiatry 1986 19 80 2
17. Shen YC Chen CH. Analysis of the data and methodology of epidemiological survey of schizophrenia in 12 Chinese regions Chin J Neurol Psychiatry 1986 19 65 9
18. Xi W. An epidemiological survey of schizophrenia inpatients Chin J Behav Med Sci 1999 34 50 1
19. Wang C. A prevalence survey of schizophrenia in Yichun city of Jiang Xi Province Sichuan Psychiatry Sci 2002 15 178 9
20. Wang SJ. An epidemiological survey on schizophrenia in Fuyang, Anhui (1984-1994) J Chin Psychol Med 2002 12 3 4
21. Cui LJ Tian GQ Zhao SM. Serum levels of prolactin and growth hormone and effect of pharmacotherapy on schizophrenia: a comparative study of risperidone and chlorpromazine Chin Mental Health J 2000 13 368 70
22. Gao ZS Wu SY. Sex differences of social psychic factors effecting on community patients with schizophrenia J Clin Psychosomatic Diseases 1999 3 1 3
23. Liu GQ Xiang MZ Yang MS. Study of the sex differences of patients with schizophrenia in the community of countryside J North Sichuan Med College 1998 13 70 1
24. Zhou Z Li X Li K Li H. Simultaneous determination of clozapine, olanzapine, risperidone and quetiapine in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry J Chromat B 2004 802 257 62
25. Li KY Cheng ZN Li X Bai XL Zhang BK Wang F et al. Simultaneous determination of quetiapine and three metabolites in human plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry Acta Pharmacol Sin 2004 25 110 4
26. Balant-Gorgia AE Androniki E. Therapeutic drug monitoring of risperidone using a new, rapid HPLC method: Reappraisal of interindividual variability factors Ther Drug Monit 1999 21 105 15
27. Spina E Avenoso A Facciola G. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia Psychopharmacology (Berl) 2001 153 238 43
28. Bondolfi G Eap CB Bertschy G. The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychiatric patients Pharmacopsychiatry 2002 35 50 6
29. Reyes JF Preskorn SH Khan A. Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses Br J Clin Pharmacol 2004 58 Suppl 1 50 7
30. Castberg I Spigset O. Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service Ther Drug Monit 2005 27 103 6
31. Transon C Lecoeur S Leemann T Beaune P Dayer P. Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes Eur J Clin Pharmacol 1996 51 79 85
32. Shu Y Cheng ZN Liu ZQ Wang LS Zhu B Huang SL et al. Interindividual variations in levels and activities of cytochrome P-450 in liver microsomes of Chinese subjects Acta Pharmacol Sin 2001 22 283 8
33. Berecz R Dorado P De La Rubia A Caceres MC Degrell I Lerena A. The role of cytochrome P450 enzymes in the metabolism of risperidone and its clinical relevance for drug interactions Curr Drug Targets 2004 5 573 9
34. Han XM Zhou HH. Polymorphism of CYP450 and cancer susceptibility Acta Pharmacol Sin 2000 21 673 9
35. Chen SQ Wedlund PJ. Correlation between cytochrome P-450 CYP2D6 (CYP2D6) genotype and phenotype Acta Pharmacol Sin 1999 20 585 8
36. Cai WM Chen B Liu YX Chu X. Dextromethorphan metabolic phenotyping in a Chinese population Acta Pharmacol Sin 1997 18 441 4
37. Boulton DW DeVane CL Liston HL. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics Life Sci 2002 71 163 9
38. Thiebaut F Tsuruo T Hamada H. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues Proc Natl Acad Sci USA 1987 84 7735 8
39. Yang HT Wang GJ. Transport and uptake characteristics of a new derivative of berberine (CPU-86017) by human intestinal epithelial cell line: Caco-2 Acta Pharmacol Sin 2003 24 1185 91
40. Rao VV Dahlheimer JL Bardgett ME. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood- cerebrospinal-fluid drug-permeability barrier Proc Natl Acad Sci USA 1999 96 3900 5
41. He L Liu GQ. Interaction of multidrug resistance reversal agents with P-glycoprotein ATPase activity on blood-brain barrier Acta Pharmacol Sin 2002 23 423 9
42. Ayrton A Morgan P. Role of transport proteins in drug absorption, distribution and excretion Xenobiotica 2001 31 469 97
43. Deberdt WG Dysken MW Rappaport SA. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia Am J Geriatr Psychiatry 2005 13 722 30
44. Knegtering R Baselmans P Castelein S. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels Am J Psychiatry 2005 162 1010 2
45. Kakihara S Yoshimura R Shinkai K Matsumoto C Goto M Kaji K et al. Prediction of response to risperidone treatment with respect to plasma concentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6 Int Clin Psychopharmacol 2005 20 71 8